Medical Condition News

RSS

Scientists discover origin of Barrett's esophagus

Dr Frank McKeon, Senior Group Leader of the Stem Cell and Developmental Biology at A*STAR's Genome Institute of Singapore, and Principal Investigator Dr Wa Xian at A*STAR's Institute of Medical Biology, together with their counterparts from the Harvard Medical School, the Brigham and Women's Hospital in Boston, and the National University of Singapore, have made the striking finding that Barrett's esophagus work, published online in the journal Cell on 24 June 2011, is essential to developing therapeutics for esophageal cancer.

28 Jun 2011

Ticagrelor drug with low-dose aspirin effective against acute coronary syndrome

When taken with higher doses of aspirin, the experimental antiplatelet drug ticagrelor was associated with worse outcomes than the standard drug, clopidogrel, but the opposite was true with lower doses of aspirin.

28 Jun 2011

Coronary CT angiography may effectively screen for heart disease in African-Americans

Researchers may have discovered one reason that African Americans are at increased risk for heart attacks and other cardiovascular events.

28 Jun 2011

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients. Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.

28 Jun 2011

Yale University: Gabapentin clinical study on epilepsy may have been a 'seeding trial'

Yale School of Medicine researchers have found that a clinical trial of the epilepsy drug gabapentin may have been a "seeding trial" used by a pharmaceutical company to promote the drug and increase prescriptions, according to a report in the June issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Leading researchers and policy experts from across the country will come together June 27 and June 28 at Mount Sinai School of Medicine in New York to examine the issue of declining enrollment in clinical trials.

28 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

FDA hearing on breast cancer drug set for this week

Genentech, the maker of Avastin, will appeal to the Food and Drug Administration to make its drug available as a treatment for breast cancer — asking for one more chance to prove its efficacy.

28 Jun 2011

RWJF launches comprehensive health care online directory for patients

The Robert Wood Johnson Foundation today launched the nation's most comprehensive online directory for patients to find reliable information on the quality of health care provided by physicians and hospitals in their communities.

28 Jun 2011

Circulation journal publishes Celladon's MYDICAR Phase 2 trial on advanced heart failure

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

28 Jun 2011

Spirituality, religion can help traumatic brain injury victims to rehabilitate

Brigid Waldron-Perrine, Ph.D., a recent graduate from Wayne State University, and her mentor, Lisa J. Rapport, Ph.D., professor of psychology at Wayne State University's College of Liberal Arts and Sciences, found that if traumatic brain injury (TBI) victims feel close to a higher power, it can help them rehabilitate. The study was recently published in Rehabilitation Psychology.

28 Jun 2011

Wildfire exposure may increase risk of heart failure

An EPA study published online Monday in Environmental Health Perspectives finds that the 2008 peat bog wildfires in NC led to an increase in emergency room visits for respiratory and cardiovascular effects.

28 Jun 2011

Scientists identify central switch responsible for epilepsy

UC Irvine and French researchers have identified a central switch responsible for the transformation of healthy brain cells into epileptic ones, opening the way to both treat and prevent temporal lobe epilepsy.

28 Jun 2011

Black church members report better quality of life than general population

Health disparities between black Americans and the rest of the nation have been well-documented in medical journals. But one study shows that blacks who identify as members of the Seventh-day Adventist Church actually report a better quality of life than the average American.

28 Jun 2011

On-X LTI announces four clinical trial results of Prosthetic Heart Valve

On-X Life Technologies, Inc. announced today that four clinical trial reports, documenting the On-X Prosthetic Heart Valve's extraordinary performance, will be presented at the upcoming meeting of the Society for Heart Valve Disease in Barcelona, Spain being held June 25-28, 2011.

28 Jun 2011